|
|
|
|
| LEADER |
03309nmm a2200301 u 4500 |
| 001 |
EB001028709 |
| 003 |
EBX01000000000000000822299 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
150402 ||| eng |
| 020 |
|
|
|a 9783319130811
|
| 100 |
1 |
|
|a Wang, Jeffrey
|e [editor]
|
| 245 |
0 |
0 |
|a Antibody-Drug Conjugates
|h Elektronische Ressource
|b The 21st Century Magic Bullets for Cancer
|c edited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro
|
| 250 |
|
|
|a 1st ed. 2015
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2015, 2015
|
| 300 |
|
|
|a X, 252 p. 59 illus., 32 illus. in color
|b online resource
|
| 505 |
0 |
|
|a 1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions
|
| 653 |
|
|
|a Pharmaceutical chemistry
|
| 653 |
|
|
|a Pharmaceutics
|
| 700 |
1 |
|
|a Shen, Wei-Chiang
|e [editor]
|
| 700 |
1 |
|
|a Zaro, Jennica L.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a AAPS Advances in the Pharmaceutical Sciences Series
|
| 028 |
5 |
0 |
|a 10.1007/978-3-319-13081-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-13081-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615.19
|
| 520 |
|
|
|a This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field
|